Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndromeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether the traditional Chinese medicine formula Xuanfei Baidu (XFBD) treats systemic inflammatory response syndrome (SIRS) by remodeling the gut microbiome. It combined animal experiments, fecal microbiota transplantation, and in-vitro compound screening. Researchers screened 51 compounds isolated from the formula for their ability to shift dysbiotic gut communities toward a healthy structure. High-scoring compounds were then combined into gut microbiome remodeling compound (GMRC) cocktails and tested for anti-inflammatory efficacy.
Who was studied?
The main model was six-week-old male C57BL/6 mice with SIRS induced by lipopolysaccharide injection, using 12 mice per group. Groups received the formula, dexamethasone, or vehicle. Fecal microbiota transplantation used XFBD-treated mice as donors, with recipients given live or heat-killed fecal material. In-vitro screening used cultured mouse cecal contents. The work also cultured fecal samples from 8 human SIRS patients and compared them with 10 healthy volunteers.
What were the most important findings?
XFBD at 1.95 g/kg improved survival, reduced spleen and lung injury, and lowered serum TNF-alpha, IL-1beta, and IL-6. It reduced Proteobacteria and raised beneficial taxa in the gut. Transplanting the remodeled microbiota reproduced the benefit, while heat-killed material did not, confirming a microbiota-dependent effect. Cocktail C, containing aucubin, gentiopicroside, syringic acid, gallic acid, p-hydroxybenzaldehyde, para-hydroxybenzoic acid, and isoimperatorin, outperformed single compounds and other cocktails. In SIRS patient fecal cultures, cocktail C raised the Firmicutes to Bacteroidetes ratio and shifted composition toward healthy volunteers.
What are the greatest implications of this study?
The work supports gut microbiome remodeling as a mechanism for herbal treatment of severe systemic inflammation. It shows a rational path from a complex formula to a defined small-molecule cocktail. The in-vitro screening approach let the team quantify and cluster 51 compounds efficiently, faster than animal trials alone. Findings remain preclinical. The in-vitro culture reduced microbial diversity, and human data were limited to fecal cultures, so clinical efficacy and safety still require testing.